ViiV at IDWeek 2024: Dr. Harmony Garges in an Illuminating Dialogue Exchange with PharmaShots

Shots: Recently at IDWeek 2024, ViiV Healthcare presented data from two real-world studies on Apretude, a long-acting injectable (LAI) for HIV pre-exposure prophylaxis. Dr. Harmony Garges, Chief Medical Officer at ViiV, shared insights from the presentations. The Opera cohort study found Apretude to be 99.7% effective in preventing HIV among participants. Additionally, the Trio Health…

BySaurabh ChaubeyDecember 16, 2024

PharmaShots Interview: Marc Meachem Shares Insight on the ViiV’s 2021 Commitment to the Community

In an interview with PharmaShots, Marc Meachem, Head of US External Affairs at ViiV Healthcare shared his views on the company's approach towards the community. He also shed light on the grants and funding received for the betterment of HIV patients. Shots: ViiV Healthcare is doubling its community investments in 2021 with the goal of disrupting the enduring…

BySenior EditorApril 7, 2021

Insights+: The US FDA New Drug Approvals in January 2021

The US FDA has approved 4 NDAs in Jan 2021, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 4 novel products in 2021. Additionally, last year in 2020, the US FDA has approved…

BySenior EditorFebruary 18, 2021

ViiV at IDWeek 2024: Dr. Harmony Garges in an Illuminating Dialogue Exchange with PharmaShots

PharmaShots Interview: Marc Meachem Shares Insight on the ViiV’s 2021 Commitment to the Community

Insights+: The US FDA New Drug Approvals in January 2021

Contact US

OUR INFORMATION

FOLLW US

ViiV at IDWeek 2024: Dr. Harmony Garges in an Illuminating Dialogue Exchange with PharmaShots

PharmaShots Interview: Marc Meachem Shares Insight on the ViiV’s 2021 Commitment to the Community

Insights+: The US FDA New Drug Approvals in January 2021

FOLLW US

Sign Up to Our Newsletter